Dendrimers are routinely synthesized as tuneable nanostructures that may be designed and regulated as a function of their size, shape, surface chemistry and interior void space. They are obtained with structural control approaching that of traditional biomacromolecules such as DNA/RNA or proteins and are distinguished by their precise nanoscale scaffolding and nanocontainer properties. As such, these important properties are expected to play an important role in the emerging field of nanomedicine. This review will describe progress on the use of these features for both targeted diagnostic imaging and drug-delivery applications. Recent efforts have focused on the synthesis and pre-clinical evaluation of a multipurpose STARBURST R PAMAM (polyamidoamine) dendrimer prototype that exhibits properties suitable for use as:
Introduction
The extraordinary level of structural control that is possible by either the Tomalia-type divergent synthesis or the Fréchet-type convergent synthesis of dendrimers [1] [2] [3] rivals that observed for precise biological nanostructures such as DNA/RNA and proteins. In fact, owing to the widely recognized mimicry of protein sizes, shapes and functionality, dendrimers are often referred to as 'artificial proteins' [4, 5] . Several critical properties that differentiate dendrimers from proteins include: (i) their core-shell architecture, wherein the core is concentrically surrounded by annular shells [i.e. generations (G)] of covalently linked branch cells that create an interior upon which terminal surface groups (Z) are presented and amplified according to the equation Z = N c N b G , where N c is core multiplicity and N b is branch cell multiplicity (see Figure 1) ; (ii) a wide range of robust non-aminoacid-derived dendrimer compositions; (iii) three-dimensional shape presentations of surface functionality defined by the shape/size of the core; (iv) a unique feature of developing interior void space capable of hosting high multiples of smaller guest molecules by surface-induced congestion; and (v) their lack of immunogenicity. These features create a wide variety of protein-like nanocontainer/scaffolding structures with demonstrated advantages compared with proteins in nanomedical applications such as drug delivery [6] , MRI (magnetic resonance imaging) and DNA/RNA transfections [7] . This very active area has been reviewed recently [8] [9] [10] .
Dendrimer properties of importance to nanomedicine
The objective of nanomedicine is to control and manipulate biomacromolecular constructs and supramolecular assemblies that are critical to living cells in order to improve the quality of human health. By definition, these constructs and assemblies are nanoscale and include entities such as proteins, DNA/RNA, viruses, cellular lipid bilayers, cellular receptor sites and antibody variable regions critical for immunology and are involved in events of nanoscale proportions. The emergence of such nanotherapeutics/diagnostics will allow a deeper understanding of human longevity and human ills that include cancer, cardiovascular disease, genetic disorders and trauma. A technology platform that provides a wide range of synthetic nanostructures that may be controlled as a function of size, shape and surface chemistry and scale to these nanobiological dimensions will be a critical first step in developing appropriate tools and a scientific basis for understanding nanomedicine. Many of the properties of these critical parameters are offered by dendrimers and include the following. (i) Monodisperse, nanoscale sizes that scale with important bio-building block dimensions Critical parameters for designing multipurpose dendrimer-based diagnostic imaging/therapy nanodevices Based on the published literature and unpublished work from our group, it is widely recognized that dendrimers may be used in two major modalities for the detection and therapeutic treatment of cancer and other diseases, namely by (i) passive targeting -nanodimension mediated via EPR (enhanced permeability retention) effect [11] involving primary tumour vascularization or organ-specific targeting [12] , and (ii) active targeting -receptor-mediated cell-specific targeting involving receptor-specific targeting groups. The combinatorial design of these nanodevices may be visualized utilizing the four construction parameters, A, B, C and Z, as described in Figure 1 . The scope, use and performance of these parameters will be selectively reviewed in the remainder of this account.
Dendrimers as nanoscale scaffolding
Dendrimer surfaces provide an excellent platform for the attachment and presentation of cell-specific targeting groups, solubility modifiers, stealth moieties that reduce immunological interactions and imaging tags. The ability to attach any or all of these molecules in a well-defined and controllable manner on to a robust dendritic surface clearly differentiates dendrimers from other vectors such as micelles, liposomes, emulsion droplets or engineered particles. The use of dendrimers as targeting vectors for diagnostic imaging, drug delivery and gene transfection had been proposed in the patent literature nearly a decade ago [13] . These applications evolved from early observations by Tomalia et al. [14] . It was noted that bioactive agents could be encapsulated into the interior of the dendrimers [15] , physically adsorbed or chemically attached [16] on to the dendrimer surface, with an option to tailor the properties of the vector to the specific needs of the active material and its therapeutic applications. Furthermore, the mathematically defined number density of surface groups allows rational attachment of desired ratios of drugs, targeting groups or functionality that may be required to obtain optimum solution, stealth, targeting or release properties with minimal dendrimer toxicity. Concurrently it was observed that appropriate surface-modified dendrimers themselves may act as nanodrugs against viruses, bacteria or tumours. Based on their now recognized 'multivalency' properties, a dendrimer-derived microbicide (i.e. VivaGel R , Starpharma) for HIV or genital herpes is in its final stage of approval by the U.S. FDA (Food and Drug Administration) (http://www.biotech-intelligence.com/html/html/ 070156594d92398317df5fd4e6324ccf.html). Historically, the first in vivo diagnostic imaging applications using dendrimer-based MRI contrast agents were demonstrated in the early 1990s by Lauterbur and colleagues [18] . In contrast with the commercial small-molecule agent (Magnevist R , Schering, AG), the dendrimer-based reagents exhibited blood pool properties and extraordinary relaxivity values when chelated gadolinium groups (Magnevist R ) were attached to PAMAM dendrimer surfaces. These generationdependent, dramatic enhancements of MRI contrast properties were some of the first examples of a 'dendritic effect'. These architecturally driven properties were unique to dendrimers as a member of the fourth major polymer architecture class (i.e. dendritic), after (i) linear, (ii) cross-linked, and (iii) branched types [19] , and have not been observed with any of the other three traditional polymer architecture types. Subsequently, the work by Kobayashi and Brechbiel [12] extended this concept by demonstrating the efficacy of 'sizemediated targeting', using the discrete dendrimer generation sizes for in vivo imaging of primary tumours via the EPR effect designing 'organ-specific diagnostic imaging modalities' and defining size-dependent mammalian excretion routes (i.e. urinary compared with bile pathways). Each of these 'passive targeting' modalities was based on appropriate use of dendrimer scaffolding dimensions for presenting the MRI imaging moieties and is illustrated in Figure 2 . One of the most effective cell-specific targeting agents presented by dendrimer scaffolding is folic acid. Membraneassociated high-affinity folate receptors are folate-binding proteins that are overexpressed on the surface of a variety of cancer cells (e.g. ovarian). They have been found to preferentially internalize dendrimers modified with folic acid into receptor-bearing cells via receptor-mediated endocytosis over normal cells. The first in vivo 'cell-specific active targeting' work with dendrimers was reported by Wiener et al. [20] against breast cancer. Functionalizing dendritic imaging agents with folic acid allowed them to be specifically directed to overexpressed folic acid receptor sites found in these cancer types. Folate-dendrimer conjugates have been shown to be well suited for targeted cancer-specific drug delivery of cytotoxic substances [21] [22] [23] . In a very recent study, branched poly(L-glutamic acid) chains were organized around PAMAM and poly(ethyleneimine) dendrimer cores to create new biodegradable polymers with improved biodistribution and targeting ability [24] . These constructs were surface terminated with PEG chains to enhance their biocompatibility, and folic acid to introduce cell-specific targeting against the epidermal KB carcinoma cell line [24] .
Carbohydrates constitute another important class of biological recognition moieties, displaying a wide variety of spatial structures because of their branching possibilities and anomericity. To achieve sufficiently high binding affinities between simple monosaccharide/oligosaccharide ligands and cell membrane receptors, these ligands have to be presented to the receptors in a multivalent or cluster fashion [25, 26] . The highly functionalized surface of dendrimers provides an excellent platform for such presentations. The design, synthesis and biomedical use of glycodendrimers, as well as their application in diagnostics and for vaccinations have been reviewed thoroughly [27] [28] [29] .
As early as 1990, Tomalia, Roberts and colleagues demonstrated conjugations of antibodies to PAMAM dendrimers [16] . More recently, antibodies specific to CD14 and PSMA (prostate-specific membrane antigen) were conjugated to a G = 5 PAMAM dendrimer bearing a fluorescein imaging tag. Cell binding and internalization of the antibody-conjugated dendrimers to antigen-expressing cells were evaluated by flow cytometry and confocal microscopy. It was found that the conjugates bound specifically to the antigen-expressing cells in a time-and dose-dependent fashion with an affinity similar to that of the free antibody. Confocal microscopy indicated that cellular internalization of the dendrimer conjugate did occur [30] .
Recently, it has been demonstrated that PAMAM dendrimers modified with VEGF (vascular endothelial growth factor) could be targeted to overexpressed tumour neovasculatures in breast carcinoma [31] .
Dendrimers as nanoscale containers
Tomalia and colleagues first demonstrated that certain carboxylated PAMAM dendrimers possess topologies and dimensional features reminiscent of regular classical micelles [14, 15] . Subsequent studies clearly described the ability to hydrophobically modify PAMAM dendrimers (i.e. with hydrophobic groups) to mimic 'inverse micelles' and demonstrated the unlimited 'guest-host' properties [8, 32] that were possible for these two types of so-called 'covalently fixed dendritic [dendri-PAMAM(NH 2 ) NcN b G]; wherein, Magnevist R and G = 3-4 are excreted completely through the kidney, G = 5 is excreted through both kidney and liver, and G = 6-9 are excreted exclusively through the liver. Note: G = 3-9 are excellent 'blood pool' agents relative to Magnevist R (i.e. diethylenetriaminepenta-acetic acid) and G = 9 is very organ-specific for the liver, presumably due to its large nanosize [12] .
micelles'. These resulting nanoscale container properties were referred to as 'unimolecular encapsulations' [33] , and have been utilized to encapsulate a wide variety of bioactive drugs, vitamins, metal salts and diagnostic imaging moieties. Particular interest has been focused on tailoring encapsulation, release and biopermeabilty features to utilize the passive and active targeting properties of dendrimers for either (i) sizemediated targeting (EPR effect), or (ii) receptor-mediated targeting to desired disease sites (organs) or cells. Many of these issues have been reviewed recently [6, 9, 10, 34] . Cisplatin is effective in treating major cancers such as ovarian, head, neck and lung cancers, as well as melanomas, lymphomas, osteosarcomas, bladder, cervical, bronchogenic and oropharyngeal carcinomas. Unfortunately, cisplatin has many adverse side effects, the most important being nephrotoxicity and cytotoxicity to non-cancerous tissue, due to the non-selective interaction between cisplatin and DNA [35] . Furthermore, the therapeutic effect of cisplatin is limited by its poor water solubility (1 mg/ml), low lipophilicity and the development of resistance to cisplatin drugs. Encapsulation of cisplatin within PAMAM dendrimers gives complexes that exhibit lower toxicity, higher accumulation in solid tumours and slower release compared with free cisplatin [36] [37] [38] [39] . Furthermore, preliminary evidence suggests that dendrimer complexes are able to bypass the P-gp (Pglycoprotein) efflux transporter [40] which may contribute Figure 3 Generalized patterns for in vitro toxicity, in vivo toxicity, biopermeability and immunogenic properties as a function of dendrimer surface functionality Note: anionic and non-charged polar surfaces in this series exhibit the most biocompatible least toxic functionality, wherein (−) indicates less of a specific property, whereas non-charged apolar and cationic surfaces exhibit higher toxicity/immunogenic properties designated by (+). From [10] . Reproduced by permission of The Royal Society of Chemistry.
to drug resistance. Cisplatin is an anti-tumour drug that exerts its effects by forming stable DNA-cisplatin complexes through intrastrand cross-links, resulting in an alteration of the DNA structure that prevents replication and initiates apoptosis. Largely pioneered by Duncan and colleagues [36] [37] [38] [39] , the tumour activity of the cisplatin-dendrimer complexes was studied using B16F10 cells. These cells were injected into C57 mice subcutaneously to provide a solid tumour model. Compared with cisplatin alone, the cisplatindendrimer complex was found to accumulate preferentially in the tumour site relatively quickly after the injection. This presumably occurs due to the EPR effect. The tumour AUC (area under the curve) for the complex was 5-fold higher than that of free cisplatin, while that in the kidney only increased 2.4 times, and accumulation in the liver was reduced [36] [37] [38] [39] .
Another recent study revealed a remarkable stability of cisplatin-dendrimer complexes, with a 20% release of cisplatin over the first 8 h, and an additional 60% release within 150 h (G. Krippner and S. Svenson, unpublished work). In vivo animal efficacy of the platinate was demonstrated using B16F10 tumour cells that were implanted subcutaneously into mice. The tumour was allowed to grow for 7 days before treatment with two doses of drug, on day 7 and day 14, providing equal capsulation (5 mg/kg) doses in both the dendrimer capsulation complex and free cisplatin. A tumour mass reduction of ∼40% compared with that for the free drug was found in this study.
The anticancer drugs adriamycin and methotrexate were encapsulated into PAMAM dendrimers (i.e. G = 3 and 4) which had been modified with PEG monomethyl ether chains (i.e. 550 and 2000 Da respectively) attached to their surfaces. The encapsulation efficiency was dependent on the PEG chain length and the generation (size) of the dendrimer, with the highest encapsulation efficiencies (on average, 6.5 adriamycin molecules and 26 methotrexate molecules per dendrimer) found for the G = 4 PAMAM terminated with PEG2000 chains. The drug release from this dendrimer was sustained at low ionic strength, again reflecting PEG chain length and dendrimer size, but fast in the isotonic solution [42] . In a related study, it was reported that the surface coverage of PAMAM dendrimers with PEG2000 chains had little influence on the encapsulation efficiency of methotrexate, but affected the release rate [43] . A similar construct involving PEG chains and PAMAM dendrimers was used to deliver the anticancer drug 5-fluorouracil. Encapsulation of 5-fluorouracil into G = 4 PAMAM dendrimers modified with carboxymethyl PEG5000 surface chains revealed reasonable drug loading, a reduced release rate and reduced haemolytic toxicity compared with the non-PEGylated dendrimer [44] .
Routes of application
Dendrimeric vectors are most commonly used as parenteral injections, either directly into the tumour tissue or intravenously for systemic delivery. However, oral drug delivery studies using the human colon adenocarcinoma cell line, Caco-2, have indicated that low-generation PAMAM dendrimers cross cell membranes, presumably through a combination of two processes, i.e. paracellular transport and adsorptive endocytosis [45] . Remarkably, the P-gp efflux transporter does not appear to affect dendrimers, therefore drug-dendrimer complexes are able to bypass the efflux transporter [40] .
Biocompatibility of dendrimers
The most important features required for the widespread use of dendrimers in nanomedicine are that they exhibit low toxicity, acceptable excretionary pathways and are nonimmunogenic. To date, the cytotoxicity of dendrimers has been studied primarily in vitro, although a few in vivo mammalian studies have been performed on mice or rats [46] . However, advanced human clinicals are currently in progress involving topical uses of an anionic surface functionalized polylysine dendrimer (i.e.VivaGel R ) which is used for the prevention of HIV and genital herpes [47, 48] . In general, the dendrimer surface functionality in combination with the generation level (size) are the two most significant parameters affecting toxicity either in vitro or in vivo. The most comprehensive review of these issues may be found in a recent paper by Boas, Christensen and Heegaard [10] , wherein, they have attempted to categorize in vitro and in vivo toxicities of dendrimers according to four general types of dendrimer surface groups as shown in Figure 3 .
Conclusions
The extraordinarily high level of synthetic control over the size, shape, surface functionality and interior void space makes these nanostructures ideal vectors for both passive and active drug delivery/diagnostic imaging applications. The bioactive agents may be encapsulated into the interior of the dendrimers, physically adsorbed or chemically attached on to the dendrimer surface, with the option to tailor the properties of the vector to the specific needs of the active material and its therapeutic applications. Furthermore, the ability to select nanoscale-sized vectors with mathematically determined numbers of surface groups and well-defined interior void space allows systematic size adjustments to determine excretionary pathways while producing optimal ratios of targeting moieties, therapy and surface groups required in combination with desired solution behaviour, excretionary pathway and acceptable toxicity margins. Finally, certain anionic surface-modified dendrimers are proving to function as safe and effective topical nanodrugs against HIV and genital herpes. These dendrimer-based nanopharmaceutics are in the final stages of human clinical testing in the U.S. FDA approval process ( [47, 48] , and http://www.biotech-intelligence. com/html/html/070156594d92398317df5fd4e6324ccf.html). This brief review of dendrimer-based nanomedical applications clearly illustrates the potential of this new 'fourth architectural class of polymers' [19, 49] and substantiates a high optimism for the future role of dendrimers in the emerging field of nanomedicine [50] .
